Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer

NCT02551159 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

823

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

BIOLOGICAL: MEDI4736
BIOLOGICAL: Tremelimumab
BIOLOGICAL: MEDI4736+Tremelimumab
BIOLOGICAL: Cetuximab
DRUG: 5-fluorouracil (5FU)
DRUG: Cisplatin
DRUG: Carboplatin

Sponsor

AstraZeneca